RELAPSING MULTIPLE SCLEROSIS (RMS)
Clinical trials for RELAPSING MULTIPLE SCLEROSIS (RMS) explained in plain language.
Never miss a new study
Get alerted when new RELAPSING MULTIPLE SCLEROSIS (RMS) trials appear
Sign up with your email to follow new studies for RELAPSING MULTIPLE SCLEROSIS (RMS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MS trial withdrawn before it began: CAR T-Cell hope on hold
Disease control TerminatedThis study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …
Matched conditions: RELAPSING MULTIPLE SCLEROSIS (RMS)
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Ublituximab shows promise for Long-Term MS control in large extension trial
Disease control OngoingThis study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS (RMS)
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simpler dosing schedule for an MS drug work just as well?
Disease control OngoingThis study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule is as safe and effective as the current approved dose. About 196 adults with relapsing MS will take part, and t…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS (RMS)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC